Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

The latest price target for Pharming (NASDAQ:PHAR) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months ...

Across the recent three months, 4 analysts have shared their insights on Pharming (NASDAQ:PHAR), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...

Revenue: US$297.2m (up 21% from FY 2023). Net loss: US$11.0m (loss widened by 4.5% from FY 2023). US$0.016 loss per share (in line with FY 2023). Revenue was in line with analyst estimates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...

1 Day PHGUF -2.24% DJIA 0.52% Russell 2K 0.43% Health Care/Life Sciences -0.24% ...

Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year ...